Short Interest in Universe Pharmaceuticals INC (NASDAQ:UPC) Increases By 1,406.0%

Universe Pharmaceuticals INC (NASDAQ:UPC – Get Free Report) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 11,506 shares, an increase of 1,406.0% from the April 30th total of 764 shares. Based on an average daily volume of 22,039 shares, the days-to-cover ratio is currently 0.5 days. Currently, 4.8% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research note on Friday, May 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Get Universe Pharmaceuticals alerts:

Get Our Latest Stock Report on UPC

Universe Pharmaceuticals Stock Up 5.6%

Shares of NASDAQ UPC traded up $0.15 during trading on Wednesday, hitting $2.76. 2,075 shares of the company were exchanged, compared to its average volume of 12,732. Universe Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $11.00. The company has a fifty day moving average price of $2.84 and a 200-day moving average price of $3.39.

About Universe Pharmaceuticals

(Get Free Report)

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.

See Also

• Five stocks we like better than Universe Pharmaceuticals
• Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
• TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
• Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
• Keysight: The AI and Defense Stock Seeing Big Price Target Boosts

Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.